Shenzhen Zhongge Biotechnology Co. Ltd. has described tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, type 2 diabetes, obesity and metabolic diseases.
Yeda Research and Development Co. Ltd. has divulged broad-spectrum coronavirus entry inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19), SARS-CoV infection and Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
University College Cardiff Consultants Ltd. has identified miglustat prodrugs reported to be useful for the treatment of lysosomal storage diseases, Down syndrome and neurodegenerative disorders.
Researchers from China Pharmaceutical University and Jiangsu Nhwa Pharmaceutical Co. Ltd. have synthesized azetidine-containing compounds acting as muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, asthma, pain, schizophrenia, pulmonary hypertension, Huntington’s disease, Parkinson’s disease and sleep disorders among others.
Erasmus Universitair Medisch Centrum Rotterdam has disclosed drug conjugates consisting of a 1,3,5-triazine core or a 1,3,5-triazinane core that is connected to two FAP-binding moieties via linkers and to a payload via another linker reported to be useful for the diagnosis and treatment of cancer.
Despite being known for more than 150 years, Duchenne muscular dystrophy (DMD) remains an untreatable disease affecting approximately 1 of every 3,500-5,000 males. Muscles in patients express no or inactive dystrophin, rendering them weak and less mobile.
Nipah virus, which circulates in fruit bats and other animals primarily in Asia and the South Pacific, causes severe neurological respiratory disease in humans and leads to death in 40%-75% of cases. The virus is endemic in Bangladesh and India, where outbreaks have occurred nearly annually since 2001.
The specific tau isoforms, such as 3-repeat (3R) and 4-repeat (4R) isoforms, and the distinct conformational strains that misfolded tau can adopt are determinants of the molecular and clinical heterogeneity observed across tauopathies.
CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SYH-2046 for heart failure after acute myocardial infarction.
RSS
